2D Catalytic, Chemodynamic, and Ferroptotic Vermiculite Nanomedicine
Source abstract
Abstract
Abstract The emerging chemodynamic therapy employs an iron‐based catalytic Fenton reaction to transform less‐reactive endogenous hydrogen peroxide within the tumor microenvironment (TME) into a highly toxic hydroxyl radical for killing cancer cells. However, the effective deployment of chemodynamic modality remains challenging, mired by a paucity of Fenton agents and overexpressed antioxidant glutathione (GSH) in cancer cells. Herein, a clay‐based 2D vermiculite nanosheet as a self‐reinforcing chemodynamic nanoagent for efficient lung cancer treatment is engineered. The engineered 2D vermiculite nanosheets are not only biocompatible with normal cells but also capable of regulating the TME through depleting GSH, which ameliorates the antioxidant activity of cancer cells. Meanwhile, GSH consumption results in increased intracellular reactive oxygen species content and enhanced lipid peroxidation level, thus inducing ferroptosis and augmenting chemodynamic cell‐killing efficacy. In particular, the ferrous oxidase hephaestin is the direct therapeutic target for 2D vermiculite nanosheets to fight against lung cancer cells. Systematic in vivo evaluations on a xenografted tumor model verify the favorable biosafety and effective tumor suppression capacity of the engineered 2D vermiculite nanosheets‐mediated chemodynamic tumor therapy by inducing desirable ferroptosis. Therefore, the developed vermiculite nanosheets represent the paradigm of 2D ferroptosis‐inducing nanomedicine for synergistic and efficient cancer treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Clinical Laboratory Medicine Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai 200030 P.R. China
Shanghai Institute of Thoracic Oncology Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai 200030 P.R. China
School of Environmental and Chemical Engineering Shanghai University Shanghai 200444 P.R. China
Materdicine Lab School of Life Sciences Shanghai University Shanghai 200444 P.R. China
Funding
National Natural Science Foundation of China
References (42)
Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1001/jamaoncol.2019.398510.1001/jamaoncol.2019.3985 ↗
3. 10.1056/NEJMoa160677410.1056/NEJMoa1606774 ↗
4. 10.1016/S0140-6736(16)30958-810.1016/S0140-6736(16)30958-8 ↗
5. 10.1186/s13045-022-01304-510.1186/s13045-022-01304-5 ↗
6. 10.1016/j.cell.2020.11.00910.1016/j.cell.2020.11.009 ↗
7. 10.1038/s41467-021-25561-z10.1038/s41467-021-25561-z ↗
8. 10.1021/acsnano.1c0560510.1021/acsnano.1c05605 ↗
9. 10.1002/adma.20200689210.1002/adma.202006892 ↗
10. 10.1002/anie.20200511110.1002/anie.202005111 ↗
11. 10.1021/acs.nanolett.1c0378610.1021/acs.nanolett.1c03786 ↗
12. 10.1002/smtd.20220017810.1002/smtd.202200178 ↗
13. 10.1021/acsnano.8b0189310.1021/acsnano.8b01893 ↗
14. 10.1002/anie.20171202710.1002/anie.201712027 ↗
15. 10.1002/EXP.2021023810.1002/EXP.20210238 ↗
16. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
17. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
18. 10.1158/0008-5472.CAN-21-154710.1158/0008-5472.CAN-21-1547 ↗
19. 10.1038/s41392-022-01046-310.1038/s41392-022-01046-3 ↗
20. 10.1038/s41586-019-1426-610.1038/s41586-019-1426-6 ↗
21. 10.1073/pnas.200682811710.1073/pnas.2006828117 ↗
22. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
23. 10.1021/acsami.9b1612410.1021/acsami.9b16124 ↗
24. 10.1021/acsnano.1c0038010.1021/acsnano.1c00380 ↗
25. 10.7150/thno.6899610.7150/thno.68996 ↗
26. 10.1039/D0CS01138J10.1039/D0CS01138J ↗
27. 10.1038/s41467-021-22278-x10.1038/s41467-021-22278-x ↗
28. 10.1016/j.addr.2022.11417810.1016/j.addr.2022.114178 ↗
29. 10.1038/s41467-020-14854-410.1038/s41467-020-14854-4 ↗
30. 10.1038/s41467-021-21436-510.1038/s41467-021-21436-5 ↗
31. 10.1039/D0CS00718H10.1039/D0CS00718H ↗
32. 10.1016/j.redox.2017.04.01610.1016/j.redox.2017.04.016 ↗
33. 10.1002/adma.20190715210.1002/adma.201907152 ↗
34. 10.1016/j.cell.2022.06.00310.1016/j.cell.2022.06.003 ↗
35. 10.1038/s41467-022-31218-210.1038/s41467-022-31218-2 ↗
36. 10.1016/j.semcancer.2021.04.00110.1016/j.semcancer.2021.04.001 ↗
37. 10.1038/s41392-021-00696-z10.1038/s41392-021-00696-z ↗
38. 10.1385/CBB:36:2-3:13710.1385/CBB:36:2-3:137 ↗
39. 10.1038/s41467-017-00350-910.1038/s41467-017-00350-9 ↗
40. 10.1016/j.ccell.2014.11.01910.1016/j.ccell.2014.11.019 ↗
41. 10.1016/j.ccell.2018.12.00910.1016/j.ccell.2018.12.009 ↗
42. 10.1038/s41467-021-21841-w10.1038/s41467-021-21841-w ↗